IMMUNITYBIO, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
IMMUNITYBIO, INC. (IBRX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $102.47 million as of 2016-09-30, per its 10-Q filed 2016-11-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2016-11-10
- 2016-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $102.47M.
- 2016-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $62.79M.
- 2016-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $39.55M.
- 2015-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $152.27M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2016-09-30 | $102.47M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $62.79M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $39.55M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $152.27M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |